力尔凡配合外照射治疗晚期非小细胞肺癌的临床研究

目的：观察力尔凡与放疗合并应用对晚期非小细胞肺癌的疗效。方法；４０例晚期非小细胞肺癌患者随机分为综合组（力尔丹＋放疗）、单纯放疗组。综合放疗开始即行为尔凡１０ｍｇ＋０．９％Ｎ．Ｓ２５０ｍｌ静点，３次／周，共６周。两组放疗方法、剂量相同。结果：综合组、单纯放疗组有效率分别是７５％、４５％，Ｐ〈０．０５。综合组治疗后与治疗前比ＣＤ４＾＋、ＣＤ４＾＋／ＣＤ８＾比值升高，Ｐ〉０．０５。ＣＤ３６＾＋升高，Ｐ

Combination of Lifein and Radiotherapy in Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)

Purpose: To observe the effect of Lifein combined with radiotherapy for advanced NSCLC. Methods: Forty cases of advanced NSCLC patients were randomized into general treatment (GT) group (Lifein radiotherapy) and radiotherapy (RT) group. At the beginning of radiotherapy in GT group, Lifein 10mg. in 0.9% NS 250ml. was dropped three times weekly. These two groups received the same method and dosage of radiation. Results: Overall response rate of GT group and RT group were 75% and 45% respectively ( P <0.05). As the effect of the GT group was compare with before treatment, CD 4 , CD 4 /CD 8 increased and CD 8 decreased ( P >0.05) and CD 56 increased ( P <0.05), while the same contrast in the RT group showed that CD 4 , CD 4 /CD 8 , CD 56 decreased significantly ( P <0.05) and CD 8 increased ( P <0.05). Significant difference of the above indices existed between these two groups after treatment.( P <0.01). Conclusion: Lifein combined with radiotherapy might impove the treatment of NSCLC and increase the cell immunity function.